List of Papers Published in 2009

List of Papers Published in 2009

  1. Breast Surgery
  2. Digestive Endoscopy & Gastrointestinal Oncology
  3. Head and Neck Surgery
  4. Hematology & Oncology
  5. Gastric, Hepatobiliary & Pancreatic Surgery
  6. Hepatobiliary & Pancreatic Oncology
  7. Colorectal (Pelvic) and Urological Surgery
  8. Plastic & Reconstructive Surgery
  9. Thoracic Oncology
  10. Thoracic Surgery
  11. Pathology Division
  12. Investigative Treatment Division
  13. Cancer Physiology Project
  14. Cancer Immunotherapy Project
  15. Functional Imaging Division
  16. Psycho-Oncology Division
  17. Particle Therapy and Radiation Oncology Division

1. Breast Surgery 

1 Imoto S, Wada N, Sakemura N, Hasebe T, Murata Y. Feasibility study on radiofrequency ablation followed by partial mastectomy for stage I breast cancer patients. Breast. 2009; Apr; 18(2): 130-4.

2. Digestive Endoscopy & Gastrointestinal Oncology

2 Sano Y, Ikematsu H, Fu KI, Emura F, Katagiri A, Horimatsu T, Kaneko K, Soetikno R, Yoshida S. Meshed capillary vessels by use of narrow-band imaging for differential diagnosis of small colorectal polyps. Gastrointest Endosc. 2009; Feb; 69(2): 278-83.
3 Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Tomino Y, Oda J, Mizutani M, Takayanagi S, Kishi D, Shinohara T, Yamada K, Matumoto J, Imamura K. Progression of a sessile serrated adenoma to an early invasive cancer within 8 months. Dig Dis Sci. 2009; Apr; 54(4): 906-9.
4 Horimatsu T, Sano Y, Kaneko K, Ikematsu H, Katagiri A, Yano T, Fu KI, Muto M, Fujii S, Ochiai A, Yoshida S. Relationship between MVD and meshed-capillaries using magnifying NBI colonoscopy in colorectal precursor lesions. Hepatogastroenterology. 2009; Mar-Apr; 56(90): 372-7.
5 Matsuda T, Fujii T, Sano Y, Kudo SE, Oda Y, Igarashi M, Iishi H, Murakami Y, Ishikawa H, Shimoda T, Kaneko K, Yoshida S. Five-year incidence of advanced neoplasia after initial colonoscopy in Japan: a multicenter retrospective cohort study. Jpn J Clin Oncol. 2009;Jul;39(7):435-42.
6 Matsuda T, Saito Y, Fujii T, Uraoka T, Nakajima T, Kobayashi N, Emura F, Ono A, Shimoda T, Ikematsu H, Fu KI, Sano Y, Fujimori T. Size does not determine the grade of malignancy of early invasive colorectal cancer. World J Gastroenterol. 2009;Jun14;15(22):2708-13.
7 Horimatsu T, Yano T, Doi T, Fujii S, Kaneko K. Complete resection of alpha-fetoprotein-producing early gastric cancer by using endoscopic submucosal dissection. Gastrointest Endosc. 2009; Mar; 69(3): 565-6.
8 Muramoto T, Kaneko K, Kuroki A, Konishi K, Ito H, Katagiri A, Kubota Y, Ohtsu A, Imawari M. Causal relationships between esophageal squamous cell carcinoma and nephrotic syndrome. Intern Med. 2009; 48(1): 65-9.
9 Kubota Y, Kaneko K, Konishi K, Ito H, Yamamoto T, Katagiri A, Muramoto T, Yano Y, Kobayashi Y, Oyama T, Kushima M, Imawari M. The onset of angiogenesis in a multistep process of esophageal squamous cell carcinoma. Front Biosci. 2009; Jan 1; 14: 3872-8.
10 Shiozawa E, Norose T, Kaneko K, Yamochi-Onizuka T, Takimoto M, Imawari M, Ota H. Clinicopathological comparison of the World Health Organization/Wotherspoon score to the Groupe dfEtude des Lymphomes de lfAdult grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma. J Gastroenterol Hepatol. 2009; Feb; 24(2): 307-15.
11 Oyama T, Kagawa N, Sugio K, Uramoto H, Hatano O, Harada N, Kaneko K, Kawamoto T, Yasumoto K. Expression of aromatase CYP19 and its relationship with parameters in NSCLC. Front Biosci. 2009; Jan1; 14: 2285-92.
12 Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K, Kogo M, Takano T, Imawari M, Hamilton SR, Issa JP. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila Pa). 2009; Sep; 2(9): 814-22.
13 Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2009; May; 39(5): 321-6.
14 Nakajima TE, Ura T, Ito Y, Kato K, Minashi K, Nihei K, Hironaka S, Boku N, Kagami Y, Muro K. A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer. Jpn J Clin Oncol. 2009; Jan; 39(1): 37-42.
15 Shirao K, Yoshino T, Boku N, Kato K, Hamaguchi T, Yasui H, Yamamoto N, Tanigawara Y, Nolting A, Yoshino S. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors. Cancer Chemother Pharmacol.2009; Aug; 64(3): 557-64.
16 Doi T, Ohtsu A, Tahara M, Tamura T, Shirao K, Yamada Y, Otani S, Yang BB, Ohkura M, Ohtsu T. Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. Int J Clin Oncol.2009; Aug;14(4): 307-14.
17 Nakamura K, Tahara M, Kiyota N, Hayashi R, Akimoto T, Fukuda H, Fujii M, Boku N. Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706). Jpn J Clin Oncol. 2009; Jul; 39(7): 460-3.
18 Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009; Nov; 10(11): 1063-9.
19 Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. Jpn J Clin Oncol. 2009; Apr; 39(4): 225-30.
20 Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, Ohtsu A, Ogino T. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol. 2009; Aug; 92(2): 266-9.
21 Imazawa M, Kojima T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, Yamazaki K, Taku K. Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer. 2009; 12(3): 153-7.
22 Ono A, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, Yamazaki K, Yoshino T, Taku K, Kojima T. Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1). Jpn J Clin Oncol. 2009; May; 39(5): 332-5.
23 Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S, Onozawa Y. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol. 2009; Dec; 14(6): 513-7.
24 Yasui H, Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. Jpn J Clin Oncol. 2009; May; 39(5): 315-20.
25 Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y, Nakajima K, Hirota S; Japanese Study Group on GIST. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol. 2009; Apr; 14(2): 143-9.
26 Fukushima-Uesaka H, Saito Y, Maekawa K, Kurose K, Sugiyama E, Katori N, Kaniwa N, Hasegawa R, Hamaguchi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Yamamoto N, Nokihara H, Kunitoh H, Ohe Y, Tamura T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Matsumura Y, Okuda H, Sawada J. Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab Pharmacokinet. 2009; 24(6):5 65-74.

3. Head and Neck Surgery

27 Hayashi R. Surgical approaches for the resection of tumors of the oral cavity and oropharynx. Oral Oncology Suppl.2009; 3(1): 20.
28 Imaizumi H, hayashi R, Ebihara E.Treatment outcome of squamous cell carcinoma of the lower alveolus. Oral Oncology Suppl. 2009; 3(1): 170.
29 Ando M, Asai M, Asakage T, Oyama W, Saikawa M, Yamazaki M, Miyazaki M, Ugumori T, Daiko H, Hayashi R. Metastatic neck disease beyond the limits of a neck dissection: attention to the epara-hyoidf area in T1/2 oral tongue cancer. Jpn J Clin Oncol. 2009; Apr; 39(4): 231-6.
30 Shinozaki T, Hayashi R, Ebihara M, Miyazaki M, Daiko H, Saikawa M. Lymph node metastasis from oral floor carcinoma. Oral Oncology Suppl. 2009; (3)1: 163.
31 Ugumori T, Muto M, Hayashi R, Hayashi T, Kishimoto S. Prospective study of early detection of pharyngeal superficial carcinoma with the narrowband imaging laryngoscope. Head Neck. 2009; Feb; 31(2): 189-94.
32 Tomidokoro Y, Hayashi R, Yamasaki M, Ishii G, Kamijo T, Ebihara S. Simultaneous squamous cell carcinoma with leiomyosarcoma of the larynx. Auris Nasus Larynx. 2009; Apr; 36(2): 239-43.
33 Kamiyama R, Saikawa M, Kishimoto S. Significance of Retropharyngeal Lymph Node Dissection in Hypopharyngeal Cancer. Jpn J Clin Oncol. 2009; Oct; 39(10): 632-7.

4. Hematology & Oncology

34 Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, Itoh K, Okamoto S, Taniwaki M, Tsukamoto N, Okumura H, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Endo K. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.Cancer Sci.2009; Jan; 100(1): 158-64.
35 Minami H, Kawada K, Sasaki Y, Tahara M, Igarashi T, Itoh K, Fujii H, Saeki T, Ozawa K, Sato H.Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice.Cancer Sci. 2009; Jan; 100(1): 144-9.
36 Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, Ando K, Taniwaki M, Watanabe T, Yamamoto J, Uchida T, Nakata M, Terauchi T, Nawano S, Matsusako M, Hayashi M, Hotta T. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci. 2009; Oct; 100(10): 1951-6.
37 Tobinai K, Watanabe T, Tanimoto K, Maruyama D, Nakata M, Itoh K, Morishima Y, Ogura M, Usui N, Kasai M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. Cancer Sci. 2009; Jul; 100(7): 1344-50.
38 Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; Nov 20; 27(33): 5594-600.
39 Mukai H. Clinical diagnosis of primary unknown cancer-the present situation and problems. Jpn J Cancer Chemother. 2009; Jun; 36(6): 915-7.
40 Ishihara M, Mukai H, Nagai S, Mukohara T. Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer. Int J Clin Oncol. 2009; Oct; 14(5): 431-5.
41 Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; Dec; 17(12): 1483-91.
42 Nakagawa K, Minami H, Kanezaki M, Mukaiyama A, Minamide Y, Uejima H, Kurata T, Nogami T, Kawada K, Mukai H, Sasaki Y, Fukuoka M. Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.Jpn J Clin Oncol. 2009; Feb; 39(2): 116-23.
43 Mukai H, Watanabe T, Ando M, Shimizu C, Katsumata N. Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed. Breast Cancer Res Treat.2009; Jan; 113(1): 123-8.
44 Shirasu M, Nagai S, Hayashi R, Ochiai A, Touhara K. Dimethyl trisulfide as a characteristic odor associated with fungating cancer wounds. Biosci Biotechnol Biochem.2009; Sep; 73(9): 2117-20.

5. Gastric, Hepatobiliary & Pancreatic Surgery

45 Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, Miyashiro I, Kaji M, Ninomiya M. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer. 2009; 12(1): 37-42.
46 Fujita T, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T. Clinical and histopathological features of remnant gastric cancers, after gastrectomy for synchronous multiple gastric cancers. J Surg Oncol.2009; Nov 1; 100(6): 466-71.
47 Konishi M, Ochiai A, Ojima H, Hasebe T, Mano M, Ohta T, Ito I, Sasaki K, Yasukawa S, Shimada K, Iwasaki M, Yanagisawa A. A new histological classification for intra-operative histological examination of the ductal resection margin in cholangiocarcinoma. Cancer Sci. 2009; 100(2): 255-260.
48 Kobayashi S, Gotohda N, Nakagohri T, Takahashi S, Konishi M, Kinoshita T. Risk factors of surgical site infection after hepatectomy for liver cancers. World J Surg.2009; Feb; 33(2): 312-7.

6. Hepatobiliary & Pancreatic Oncology

49 Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol. 2009; Dec; 65(1): 113-20.
50 Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, Sugiyama E, Kim SR, Hasegawa R, Saito Y, Yoshida T, Saijo N, Sawada J. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer. 2009; Mar 24; 100(6): 870-3.
51 Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T. Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol. 2009; May 1; 27(13): 2261-8.
52 Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009; Jan; 63(2): 313-9.
53 Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, Takaue Y, Heike Y. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2009; Dec; 39(12): 797-806.
54 Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology. 2009; 77(3-4): 217-23.
55 Seki Y, Okusaka T, Ikeda M, Morizane C, Ueno H. Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. Jpn J Clin Oncol. 2009; Nov; 39(11): 751-5.
56 Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim SR, Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada JI, Yoshida T. A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. Pharmacogenomics J. 2009; Apr; 9(2): 137-46.
57 Haga K, Tomioka A, Liao CP, Kimura T, Matsumoto H, Ohno I, Hermann K, Logg CR, Jiao J, Tanaka M, Hirao Y, Wu H, Kruse CA, Roy-Burman P, Kasahara N. PTEN knockout prostate cancer as a model for experimental immunotherapy.J Urol. 2009; Jan; 181(1): 354-62.

7. Colorectal (Pelvic) and Urological Surgery

58 Ito M, Sugito M, Kobayashi A, Nishizawa Y, Tsunoda Y, Saito N. Influence of learning curve on short-term results after laparoscopic resection for rectal cancer. Surg Endosc. 2009; Feb; 23(2): 403-8.
59 Ito M, Saito N, Sugito M, Kobayashi A, Nishizawa Y, Tsunoda Y. Analysis of clinical factors associated with anal function after intersphincteric resection for very low rectal cancer. Dis Colon Rectum. 2009; Jan; 52(1): 64-70.
60 Koda K, Yasuda H, Hirano A, Kosugi C, Suzuki M, Yamazaki M, Tezuka T, Higuchi R, Tsuchiya H, Saito N. Evaluation of postoperative damage to anal sphincter/levator ani muscles with three-dimensional vector manometry after sphincter-preserving operation for rectal cancer. J Am Coll Surg. 2009; Mar; 208(3): 362-7.
61 Saito N, Sugito M, Ito M, Kobayashi A, Nishizawa Y, Yoneyama Y, Nishizawa Y, Minagawa N. Oncologic outcome of intersphincteric resection for very low rectal cancer. World J Surg. 2009; Aug; 33(8): 1750-6.
62 Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg. 2009; Sep; 96(9): 1058-65.
63 Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, Yamaguchi S, Kondo Y, Saito N, Kato T, Ohue M, Higashino M, Moriya Y; Colorectal Cancer Study Group of the Japan Clinical Oncology Group. Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol. 2009; Oct; 14(5): 416-20.

8. Plastic & Reconstructive Surgery

64 Yasumura T, Sakuraba M, Kimata Y, Nakatsuka T, Hayashi R, Ebihara S, Hata Y. Functional outcomes and reevaluation of esophageal speech after free jejunal transfer in two hundred thirty-six cases. Ann Plast Surg. 2009; Jan; 62(1): 54-8.
65 Kadota H, Sakuraba M, Kimata Y, Hayashi R, Ebihara S, Kato H. Larynx-preserving esophagectomy and jejunal transfer for cervical esophageal carcinoma.Laryngoscope.2009; Jul; 119(7): 1274-80.
66 Kadota H, Sakuraba M, Kimata Y, Yano T, Hayashi R. Analysis of thrombosis on postoperative day 5 or later after microvascular reconstruction for head and neck cancers. Head Neck. 2009; May; 31(5): 635-41.
67 Sakuraba M, Asano T, Miyamoto S, Hayashi R, Yamazaki M, Miyazaki M, Ugumori T, Daiko H, Kimata Y. A new flap design for tongue reconstruction after total or subtotal glossectomy in thin patients. J Plast Reconstr Aesthet Surg. 2009; Jun; 62(6): 795-9.
68 Sakuraba M, Asano T, Yano T, Yamamoto S, Moriya Y. Reconstruction of an enterocutaneous fistula using a superior gluteal artery perforator flap. J Plast Reconstr Aesthet Surg. 2009; Jan; 62(1): 108-11.
69 Yano T, Sakuraba M, Asano T, Sarukawa S. Head and neck reconstruction with the deep inferior epigastric perforator flap: a report of two cases. Microsurgery. 2009; 29(4): 287-92.

9. Thoracic Oncology

70 Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; Sep 3; 361(10): 947-57.
71 Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, Yokoyama A, Watanabe K, Noda K, Saijo N; JCOG Lung Cancer Study Group, Tokyo, Japan. A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 2009; Feb 10; 100(3): 464-9.
72 Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kudoh S, Yokota S, Matsui K, Semba H, Nakagawa K, Takada Y, Ando M, Shibata T, Saijo N. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol. 2009; May; 20(5): 835-41.
73 Kunitoh H, Tamura T, Shibata T, Nakagawa K, Takeda K, Nishiwaki Y, Osaki Y, Noda K, Yokoyama A, Saijo N; JCOG Lung Cancer Study Group, Tokyo, Japan. A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605). Br J Cancer. 2009; Nov 3; 101(9): 1549-54.
74 Kim YH, Kubota K, Goto K, Yoh K, Niho S, Ohmatsu H, Saijo N, Nishiwaki Y. A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2. Jpn J Clin Oncol. 2009; Sep; 39(9): 576-81.
75 Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009; Jul; 45(11): 1950-1958.
76 Sanuki-Fujimoto N, Ishikura S, Hayakawa K, Kubota K, Nishiwaki Y, Tamura T. Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202. Radiat Oncol. 2009; Jun 2; 4: 16.
77 Shiraishi K, Kohno T, Kunitoh H, Watanabe S, Goto K, Nishiwaki Y, Shimada Y, Hirose H, Saito I, Kuchiba A, Yamamoto S, Yokota J. Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis.2009; Jan; 30(1): 65-70.
78 Naito Y, Goto K. Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. Clinical Medicine: Therapeutics 1. 2009; 1027-40.

10. Thoracic Surgery

79 Hishida T, Yoshida J, Nishimura M, Ishii G, Nagai K. Extraskeletal osteosarcoma arising in anterior mediastinum: brief report with a review of the literature. J Thorac Oncol. 2009; Jul; 4(7): 927-9.
80 Yoshida J, Nagai K, Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Miyaoka E, Japanese Joint Committee for Lung Cancer Registration. Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database. J Thorac Oncol. 2009; Aug; 4(8): 959-63.

11. Pathology Division

81 Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer. 2009; Sep 15; 125(6): 1276-84.
82 Ito TK, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, Ochiai A. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood. 2009; Mar 5; 113(10): 2363-9.
83 Maeda H, Yonou H, Yano K, Ishii G, Saito S, Ochiai A. Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5. Biochem Biophys Res Commun. 2009; Apr 10; 381(3): 311-6.
84 Kimura T, Kuwata T, Ashimine S, Yamazaki M, Yamauchi C, Nagai K, Ikehara A, Feng Y, Dimitrov DS, Saito S, Ochiai A.Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res.2009; Jan1; 16(1): 121-9.
85 Zhang S, Hayashi R, Fujii M, Hasegawa Y, Yoshino K, Fukayama M, Ochiai A. Total microvessel perimeter per tumor area is a predictor of radiosensitivity in early-stage glottic carcinoma. Int J Radiat Oncol Biol Phys. 2009; Mar 15; 73(4): 1104-9.
86 Kojima M, Ishii G, Yamane Y, Nishizawa Y, Saito N, Ochiai A. Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy. Pathol Int.2009; Dec; 59(12): 857-62.
87 Shomori K, Ochiai A, Akimoto S, Ino Y, Shudo K, Ito H, Hirohashi S. Tyrosine-phosphorylation of the 12th armadillo-repeat of beta-catenin is associated with cadherin dysfunction in human cancer. Int J Oncol. 2009; Sep; 35(3): 517-24.
88 Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, J?nne PA, Saijo N, Minami H. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett. 2009; Sep 8; 282(1): 14-24.
89 Ito T, Ishii G, Nagai K, Nagano T, Kojika M, Murata Y, Atsumi N, Nishiwaki Y, Miyazaki E, Kumamoto T, Ochiai A. Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer. 2009; Mar; 63(3): 418-24.
90 Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009; Apr; 64(1): 98-104.
91 Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, Ochiai A. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer. 2009; Jul; 65(1): 105-11.
92 Shimada Y, Ishii G, Nagai K, Atsumi N, Fujii S, Yamada A, Yamane Y, Hishida T, Nishimura M, Yoshida J, Ikeda N, Ochiai A. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci. 2009; Nov; 100(11): 2054-9.
93 Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, Ota SJ, Murata Y, Nagai K, Ochiai A. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. Mod Pathol. 2009; Oct; 22(10): 1341-50.
94 Nakao M, Ishii G, Nagai K, Kawase A, Kenmotsu H, Kon-No H, Hishida T, Nishimura M, Yoshida J, Ochiai A. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer. 2009; Jun 15; 115(12): 2732-43.
95 Higashi M, Sugaya Y, Soeta S, Yokota A, Ishii G, Harigaya K. CD44 expression during tumor progression of follicular lymphoma. Oncol Rep. 2009; Nov; 22(5): 1135-40.
96 Saegusa M, Hashimura M, Kuwata T, Okayasu I. Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol. 2009; Jun; 174(6): 2107-15.
97 Miyazaki K, Yamasaki N, Oda H, Kuwata T, Kanno Y, Miyazaki M, Komeno Y, Kitaura J, Honda Z, Warming S, Jenkins NA, Copeland NG, Kitamura T, Nakamura T, Honda H. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.Blood. 2009; May 7; 113(19): 4702-10.

12. Investigative Treatment Division

98 Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009; Apr; 100(4): 572-9.
99 Matsumura Y. NK012. Drugs of the Future(Thomson Reuters). 2009; 34(4): 276-81.
100 Nagano T, Yasunaga M, Goto K, Kenmotsu H, Koga Y, Kuroda JI, Nishimura Y, Sugino T, Nishiwaki Y, Matsumura Y. Antitumor Activity of NK012 Combined with Cisplatin against Small Cell Lung Cancer and Intestinal Mucosal Changes in Tumor-Bearing Mouse after Treatment. Clin Cancer Res. 2009; Jul1; 15(13): 4348-55.
101 Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Saito Y, Matsumura Y. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma.Int J Cancer. 2009; Jun 1; 124(11): 2505-11.
102 Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H, Matsumura Y. Detection of the DNA point mutation of colorectal cancer cells isolated from feces stored under different conditions. Jpn J Clin Oncol. 2009; Jan; 39(1): 62-9.
103 Sai K, Saito Y, Itoda M, Fukushima-Uesaka H, Nishimaki-Mogami T, Ozawa S, Maekawa K, Kurose K, Kaniwa N, Kawamoto M, Kamatani N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Matsumura Y, Ohtsu A, Saijo N, Sawada J. Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug Metab Pharmacokinet. 2008; 23(2): 139-47.
104 Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada JI, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol. 2009.
105 Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Sawada J. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos. 2009; Feb; 37(2): 272-6.

13. Cancer Physiology Project

106 Tatemichi M, Ogura T, Esumi H. Impact of inducible nitric oxide synthase gene on tumor progression. Eur J Cancer Prev.2009; Feb; 18(1): 1-8.
107 Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H, Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009; Jun1; 69(11): 4918-25.
108 Tsuchihara K, Fujii S, Esumi H. Autophagy and cancer: dynamism of the metabolism of tumor cells and tissues. Cancer Lett. 2009; Jun 18; 278(2): 130-8.
109 Tomitsuka E, Kita K, Esumi H. Regulation of succinate-ubiquinone reductase and fumarate reductase activities in human complex II by phosphorylation of its flavoprotein subunit. Proc Jpn Acad Ser B Phys Biol Sci. 2009; 85(7): 258-65.
110 Awale S, Miyamoto T, Linn TZ, Li F, Win NN, Tezuka Y, Esumi H, Kadota S. Cytotoxic constituents of Soymida febrifuga from Myanmar. J Nat Prod. 2009; Sep; 72(9): 1631-6.
111 Li F, Awale S, Zhang H, Tezuka Y, Esumi H, Kadota S. Chemical constituents of propolis from Myanmar and their preferential cytotoxicity against a human pancreatic cancer cell line.J Nat Prod. 2009; Jul; 72(7): 1283-7.
112 Ichinoseki-Sekine N, Naito H, Tsuchihara K, Kobayashi I, Ogura Y, Kakigi R, Kurosaka M, Fujioka R, Esumi H. Provision of a voluntary exercise environment enhances running activity and prevents obesity in Snark-deficient mice. Am J Physiol Endocrinol Metab. 2009; May; 296(5): E1013-21.
113 Tsuchihara K, Suzuki Y, Wakaguri H, Irie T, Tanimoto K, Hashimoto S, Matsushima K, Mizushima-Sugano J, Yamashita R, Nakai K, Bentley D, Esumi H, Sugano S. Massive transcriptional start site analysis of human genes in hypoxia cells. Nucleic Acids Res. 2009; Apr; 37(7): 2249-63.
114 Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A, Tsao MS, Iovanna JL, Jurisicova A, Melino G, Mak TW. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci U S A.2009; Jan 20; 106(3): 797-802.
115 Sugiyama K, Yamaguchi M, Kuroda J, Takanashi M, Ishikawa Y, Fujii H, Ishii T, Esumi H. Improvement of radiation-induced healing delay by etanercept treatment in rat arteries.Cancer Sci. 2009; Aug; 100(8): 1550-5.

14. Cancer Immunotherapy Project

116 Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.Int J Oncol.2009; Mar; 34(3): 649-56.
117 Hayashi E, Motomura Y, Shirakawa H, Yoshikawa T, Oba N, Nishinakagawa S, Mizuguchi Y, Kojima T, Nomura K, Nakatsura T. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncol Rep. 2009; Jul; 22(1): 149-54.
118 Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci.2009; Aug; 100(8): 1403-7.
119 Ikuta Y, Hayashida Y, Hirata S, Irie A, Senju S, Kubo T, Nakatsura T, Monji M, Sasaki Y, Baba H, Nishimura Y. Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. Cancer Sci.2009; Jan; 100(1): 132-7.

15. Functional Imaging Division

120 Nakamoto Y, Togashi K, Kaneta T, Fukuda H, Nakajima K, Kitajima K, Murakami K, Fujii H, Satake M, Tateishi U, Kubota K, Senda M Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study. Jpn J Clin Oncol. 2009; 39: 297-302.
121 Kaneta T, Takahashi S, Fukuda H, Arisaka Y, Oriuchi N, Hayashi T, Fujii H, Terauchi T, Tateishi U, Kubota K, Hara T, Nakamoto Y, Kitajima K, Murakami K. Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: a summary of a Japanese multicenter study. Ann Nucl Med. 2009; 23: 459-64.
122 Kitajima K, Murakami K, Kanegae K, Tamaki N, Kaneta T, Fukuda H, Nakajima K, Fujii H, Tateishi U, Kubota K, Suga T, Nakamoto Y. Clinical impact of whole body FDG-PET for recurrent biliary cancer: a multicenter study. Ann Nucl Med. 2009; 23: 709-15.
123 Inoue K, Sato T, Kitamura H, Hirayama A, Kurosawa H, Tanaka T, Fukushi M, Moriyama N, Fujii H. An anthropomorphic pelvis phantom for optimization of the diagnosis of lymph node metastases in the pelvis.Ann Nucl Med.2009; 23: 245-5.
124 Yamaguchi M, Mitsumori F, Watanabe H, Takaya N, Minami M. Visualization of seminiferous tubules in rat testes in normal and diseased conditions by high-resolution MRI. Magn Reson Med. 2009; 62: 637-44.
125 Takeuchi H, Fujii H, Ando N, Ozawa S, Saikawa Y, Suda K, Oyama T, Mukai M, Nakahara T, Kubo A, Kitajima M, Kitagawa Y. Validation study of radio-guided sentinel lymph node navigation in esophageal cancer. Ann Surg. 2009; 249: 757-63.
126 Kawase T, Fujii H, Nakahara T, Shigematsu N, Kubo A, Kosuda S. Intense accumulation of Tc-99m MDP in pericardial metastasis from breast cancer. Clin Nucl Med.2009; 34: 173-4.
127 Akiyama N, Umeda IO, Sogo S, Nishigori H, Tsujimoto M, Natori S. 5-S-GAD, a novel radical scavenging compound, prevents lens opacity development. Free Radic Biol Med. 2009; 46: 511-9.

16. Psycho-Oncology Division

128 Akechi T, Ietsugu T, Sukigara M, Okamura H, Nakano T, Akizuki N, Okamura M, Shimizu K, Okuyama T, Furukawa TA, Uchitomi Y. Symptom indicator of severity of depression in cancer patients: a comparison of the DSM-IV criteria with alternative diagnostic criteria.Gen Hosp Psychiatry. 2009; May-Jun; 31(3): 225-32.
129 Sanjo M, Morita T, Miyashita M, Shiozaki M, Sato K, Hirai K, Shima Y, Uchitomi Y. Caregiving Consequences Inventory: a measure for evaluating caregiving consequences from the bereaved family memberfs perspective. Psychooncology. 2009; Jun; 18(6): 657-66.
130 Morita T, Murata H, Kishi E, Miyashita M, Yamaguchi T, Uchitomi Y; Japanese Spiritual Care Task Force. Meaninglessness in terminally ill cancer patients: a randomized controlled study. J Pain Symptom Manage. 2009; Apr; 37(4): 649-58.
131 Miyashita M, Morita T, Ichikawa T, Sato K, Shima Y, Uchitomi Y. Quality indicators of end-of-life cancer care from the bereaved family membersf perspective in Japan. J Pain Symptom Manage.2009; Jun; 37(6): 1019-26.
132 Fujimori M, Uchitomi Y. Preferences of cancer patients regarding communication of bad news: a systematic literature review. Jpn J Clin Oncol. 2009; Apr; 39(4): 201-16.
133 Akechi T, Okamura H, Okuyama T, Furukawa TA, Nishiwaki Y, Uchitomi Y. Psychosocial factors and survival after diagnosis of inoperable non-small cell lung cancer. Psychooncology. 2009; Jan; 18(1): 23-9.
134 Nakaya N, Bidstrup PE, Eplov LF, Saito-Nakaya K, Kuriyama S, Tsuji I, Uchitomi Y, Johansen C. Mental vulnerability and survival after cancer. Epidemiology. 2009; Nov; 20(6): 916-20.

17. Particle Therapy and Radiation Oncology Division

135 Kohno R, Kitou S, Hirano E, Kameoka S, Goka T, Nishio T, Miyagishi T, Ariji T, Kawashima M, Ogino T. Dosimetric verification in inhomogenous phantom geometries for the Xio radiotherapy treatment planning system with 6-MV photon beams. Radiol Phys Technol. 2009; 2: 87-96.
136 Tsujii H, Akagi T, Akahana K, Uwamino Y, Ono T, Kanai T, Kohno R, sakae T, Shimizu M, Urakabe E, Nakayama T, Nakamura T, Nishio T, Nishizawa K, Nishizawa K, Fukuda S, Matsufuji N, Yamashita H, Yonai S. Research on radiation protection in the application of new technologies for proton and heavy ion radiotherapy.Jpn J Med Phys. 2009; 28: 172-206.

  


 Table of Contents